CrackitToday App

Phase 3 Trials of Its First Indigenous Dengue Vaccine

Kumari Sonali

Phase 3 Trials of Its First Indigenous Dengue Vaccine:

India has enrolled over 8,000 participants in Phase 3 trials of its first indigenous dengue vaccine, developed by Panacea Biotec and supported by ICMR.DengiAll – a tetravalent dengue vaccine designed to protect against all four dengue virus serotypes (DENV-1 to DENV-4).
Origin: Derived from the TV003/TV005 strain originally developed by the U.S. National Institutes of Health (NIH) and licensed to Indian firms.
Organisations Involved: ICMR (Indian Council of Medical Research): Primary funder and scientific lead. Panacea Biotec: Vaccine developer holding process patents and leading formulation trials.

...Read more on our test console

...Read these too

  • DNA Vaccine Against Dengue

    DNA Vaccine Against Dengue: India’s first prospective DNA vaccine against dengue is under clinical trials. The DNA vaccine has been in development since 2019 by scientists from the National Centre…

  • Vaccine Hesitancy

    Vaccine Hesitancy:   While last year, before the second wave, vaccine hesitancy was ascribed to the low uptake, it is quite likely now that people are exercising their option of…

  • Indigenous People

    Indigenous People: At the 15th Conference of Parties (COP15) to the United Nations Convention on Biological Diversity (CBD), a group representing indigenous people stressed that the Post-2020 Global Biodiversity Framework…